Sartorius Stedim Biotech S.A.
MarketLine (a Datamonitor Company)
26 Jan 2015
Available for Immediate Download
Sartorius Stedim Biotech S.A. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Sartorius Stedim Biotech S.A. required for business and competitor intelligence needs - Intelligence on Sartorius Stedim Biotech S.A.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Sartorius Stedim Biotech S.A., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Sartorius Stedim Biotech (SSB) (formerly Stedim Biosystems) is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. The company operates in Europe, the Americas, Africa and Asia Pacific. It is headquartered in Aubagne, France, and employs around 3,300 people. The company recorded revenues of E588.4 million (approximately $781.5 million) in the fiscal year ended December 2013, an increase of 8.2% over 2012. The company's operating profit was E101.3 million (approximately $134.6 million) in fiscal 2013, an increase of 18.4% over 2012. Its net profit was E66.3 million (approximately $88 million) in fiscal 2013, an increase of 16.8% over 2012. Reasons to Purchase: - Gain understanding of Sartorius Stedim Biotech S.A. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Sartorius Stedim Biotech S.A. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Sartorius Stedim Biotech S.A. your competitors' business structure, strategy and prospects